Therapeutic options have remained limited for the treatment of bipolar disorder (BD) where, according to the National Alliance on Mental Illness, about 2.6% of the U.S. population is diagnosed with the condition and nearly 83% of those cases classified as severe. Historically, there has been a lack of biopharma industry investment in neurology/psychiatric conditions. However, there are signs that the situation is changing, with exciting new research into the underlying biology of BD paving the way for the discovery of promising therapeutic targets. That has catalyzed a noticeable upswing in investment in research and development and the establishment of strategic partnerships helping expand the product pipeline.